Understanding the Securities Fraud Class Action
The Law Offices of Frank R. Cruz are alerting investors regarding a significant opportunity connected to Applied Therapeutics, Inc. (APLT). Investors are reminded of the impending deadline to participate as lead plaintiffs in a class action lawsuit pertaining to securities fraud.
Key Dates and Participation Information
The deadline to engage as a lead plaintiff in the lawsuit is set for February 18, 2025. Those who acquired shares of Applied Therapeutics between January 3, 2024, and December 2, 2024, may have experienced financial losses and are encouraged to take action now.
Impact on Investors
Following critical disclosures from Applied Therapeutics on November 27, 2024, regarding a Complete Response Letter (CRL) from the FDA, investor sentiment plummeted. The response indicated that the FDA could not approve the New Drug Application (NDA) concerning the company's drug, govorestat, in the form submitted. This announcement led to a drastic decline in Applied Therapeutics' stock price by $6.54, equating to a 76.3% drop, which closed at $2.03 per share by November 29, 2024.
Further Decline and Class Action Allegations
The situation worsened as the company revealed additional regulatory challenges on December 2, 2024, including receiving a warning letter from the FDA regarding electronic data capture and crucial dosing errors during clinical trials. This news propelled the stock further down to $1.29 per share by December 5, 2024, a decrease of 26.3% over several trading days, exacerbating the losses faced by investors.
Specific Allegations in the Lawsuit
The complaint lodged against the company claims that throughout the class period, the defendants engaged in materially misleading behavior, failing to disclose critical information that could have affected investors' decisions. These omissions included non-compliance with clinical trial protocols and the associated risks that could significantly jeopardize the NDA review process by the FDA.
What Investors Should Do
For those who purchased or acquired Applied Therapeutics securities during the specified period, it's essential to act quickly to safeguard your rights and explore your options within this class action. Engaging with legal professionals knowledgeable about securities fraud is advisable.
Contact Information for Assistance
If you're interested in participating or require further insights into your rights concerning the class action lawsuit, reach out to:
Frank R. Cruz
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Email: info@frankcruzlaw.com
Phone: 310-914-5007
Website: www.frankcruzlaw.com
Frequently Asked Questions
What is the deadline to participate in the lawsuit against Applied Therapeutics?
The deadline to join as a lead plaintiff in the class action lawsuit is February 18, 2025.
What prompted the significant stock price drop for Applied Therapeutics?
The stock price drop was primarily due to the company's disclosures regarding the FDA's Complete Response Letter and a subsequent warning letter concerning their clinical trials.
Who is eligible to participate in the class action lawsuit?
Investors who acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, are eligible to participate.
How can I get more information about the lawsuit?
For more information, interested investors can reach out to The Law Offices of Frank R. Cruz via email or phone.
What should I do if I lost money investing in Applied Therapeutics?
If you lost money on your investment, consider contacting a legal professional to discuss your options in joining the class action lawsuit.
